Advanced Search

Project: Medication Use for the Risk Reduction of Primary Breast Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Entered Retrospectively]

Public Report Complete

Project Summary

Title and Description

Key Questions

Associated Extraction Forms

Title Created by Key Questions Addressed Form Notes
Key Questions 1-4 Sara Grusing 1, 2, 3, 4

Associated Studies (each link opens a new tab)

Title Author Year
Diagnostic accuracy of the Gail model in the Black Women's Health Study. Adams-Campbell LL., Makambi KH., Palmer JR., Rosenberg L. -- Not Found --
Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. Amir E., Evans DG., Shenton A., Lalloo F., Moran A., Boggis C., Wilson M., Howell A. 2003
Prospective breast cancer risk prediction model for women undergoing screening mammography. Barlow WE., White E., Ballard-Barbash R., Vacek PM., Titus-Ernstoff L., Carney PA., Tice JA., Buist DS., Geller BM., Rosenberg R., Yankaskas BC., Kerlikowske K. 2006
Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. Boughey JC., Hartmann LC., Anderson SS., Degnim AC., Vierkant RA., Reynolds CA., Frost MH., Pankratz VS. 2010
Contribution of three components to individual cancer risk predicting breast cancer risk in Italy. Boyle P., Mezzetti M., La Vecchia C., Franceschi S., Decarli A., Robertson C. 2004
Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. Brentnall AR., Harkness EF., Astley SM., Donnelly LS., Stavrinos P., Sampson S., Fox L., Sergeant JC., Harvie MN., Wilson M., Beetles U., Gadde S., Lim Y., Jain A., Bundred S., Barr N., Reece V., Howell A., Cuzick J., Evans DG. 2015
Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. Chen J., Pee D., Ayyagari R., Graubard B., Schairer C., Byrne C., Benichou J., Gail MH. 2006
Predicting risk of breast cancer in postmenopausal women by hormone receptor status. Chlebowski RT., Anderson GL., Lane DS., Aragaki AK., Rohan T., Yasmeen S., Sarto G., Rosenberg CA., Hubbell FA. 2007
Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Colditz GA., Rosner B. 2000
Risk factors for breast cancer according to estrogen and progesterone receptor status. Colditz GA., Rosner BA., Chen WY., Holmes MD., Hankinson SE. 2004
Validation studies for models projecting the risk of invasive and total breast cancer incidence. Costantino JP., Gail MH., Pee D., Anderson S., Redmond CK., Benichou J., Wieand HS. 1999
Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition cohort. Decarli A., Calza S., Masala G., Specchia C., Palli D., Gail MH. 2006
Absolute risk models for subtypes of breast cancer. Gail MH., Anderson WF., Garcia-Closas M., Sherman ME. 2007
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Gail MH., Brinton LA., Byar DP., Corle DK., Green SB., Schairer C., Mulvihill JJ. 1989
Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts. Li K., Anderson G., Viallon V., Arveux P., Kvaskoff M., Fournier A., Krogh V., Tumino R., Sánchez MJ., Ardanaz E., Chirlaque MD., Agudo A., Muller DC., Smith T., Tzoulaki I., Key TJ., Bueno-de-Mesquita B., Trichopoulou A., Bamia C., Orfanos P., Kaaks R., Hüsing A., Fortner RT., Zeleniuch-Jacquotte A., Sund M., Dahm CC., Overvad K., Aune D., Weiderpass E., Romieu I., Riboli E., Gunter MJ., Dossus L., Prentice R., Ferrari P. 2018
Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. Matsuno RK., Costantino JP., Ziegler RG., Anderson GL., Li H., Pee D., Gail MH. 2011
Risk factor modification and projections of absolute breast cancer risk. Petracci E., Decarli A., Schairer C., Pfeiffer RM., Pee D., Masala G., Palli D., Gail MH. 2011
Breast cancer risk prediction with a log-incidence model: evaluation of accuracy. Rockhill B., Byrne C., Rosner B., Louie MM., Colditz G. 2003
Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. Rockhill B., Spiegelman D., Byrne C., Hunter DJ., Colditz GA. 2001
Evaluation of a breast cancer risk prediction model expanded to include category of prior benign breast disease lesion. Tamimi RM., Rosner B., Colditz GA. 2010
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Tice JA., Cummings SR., Smith-Bindman R., Ichikawa L., Barlow WE., Kerlikowske K. 2008
Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. Tice JA., Miglioretti DL., Li CS., Vachon CM., Gard CC., Kerlikowske K. 2015
A breast cancer prediction model incorporating familial and personal risk factors. Tyrer J., Duffy SW., Cuzick J. 2004
Breast cancer risk assessment in women aged 70 and older. Vacek PM., Skelly JM., Geller BM. 2011
Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. Warwick J., Birke H., Stone J., Warren RM., Pinney E., Brentnall AR., Duffy SW., Howell A., Cuzick J. 2014
Effect of Raloxifene on all-cause mortality. Grady D., Cauley JA., Stock JL., Cox DA., Mitlak BH., Song J., Cummings SR. 2010
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. Martino S., Cauley JA., Barrett-Connor E., Powles TJ., Mershon J., Disch D., Secrest RJ., Cummings SR. 2004
Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Barrett-Connor E., Cauley JA., Kulkarni PM., Sashegyi A., Cox DA., Geiger MJ. 2004
Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. Barrett-Connor E., Grady D., Sashegyi A., Anderson PW., Cox DA., Hoszowski K., Rautaharju P., Harper KD. 2002
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. Barrett-Connor E., Mosca L., Collins P., Geiger MJ., Grady D., Kornitzer M., McNabb MA., Wenger NK. 2006
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Cauley JA., Norton L., Lippman ME., Eckert S., Krueger KA., Purdie DW., Farrerons J., Karasik A., Mellstrom D., Ng KW., Stepan JJ., Powles TJ., Morrow M., Costa A., Silfen SL., Walls EL., Schmitt H., Muchmore DB., Jordan VC., Ste-Marie LG. 2001
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. Cummings SR., Eckert S., Krueger KA., Grady D., Powles TJ., Cauley JA., Norton L., Nickelsen T., Bjarnason NH., Morrow M., Lippman ME., Black D., Glusman JE., Costa A., Jordan VC. 1999
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Cuzick J., Sestak I., Cawthorn S., Hamed H., Holli K., Howell A., Forbes JF. 2015
Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study. Day R., Ganz PA., Costantino JP. 2001
A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. DeCensi A., Bonanni B., Maisonneuve P., Serrano D., Omodei U., Varricchio C., Cazzaniga M., Lazzeroni M., Rotmensz N., Santillo B., Sideri M., Cassano E., Belloni C., Muraca M., Segnan N., Masullo P., Costa A., Monti N., Vella A., Bisanti L., D'Aiuto G., Veronesi U. 2013
Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Decensi A., Maisonneuve P., Rotmensz N., Bettega D., Costa A., Sacchini V., Salvioni A., Travaglini R., Oliviero P., D'Aiuto G., Gulisano M., Gucciardo G., del Turco MR., Pizzichetta MA., Conforti S., Bonanni B., Boyle P., Veronesi U. 2005
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. Delmas PD., Ensrud KE., Adachi JD., Harper KD., Sarkar S., Gennari C., Reginster JY., Pols HA., Recker RR., Harris ST., Wu W., Genant HK., Black DM., Eastell R. 2002
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Delmas PD., Genant HK., Crans GG., Stock JL., Wong M., Siris E., Adachi JD. 2003
Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene. Duvernoy CS., Kulkarni PM., Dowsett SA., Keech CA. -- Not Found --
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Ettinger B., Black DM., Mitlak BH., Knickerbocker RK., Nickelsen T., Genant HK., Christiansen C., Delmas PD., Zanchetta JR., Stakkestad J., Glüer CC., Krueger K., Cohen FJ., Eckert S., Ensrud KE., Avioli LV., Lips P., Cummings SR. 1999
Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. Grady D., Cauley JA., Geiger MJ., Kornitzer M., Mosca L., Collins P., Wenger NK., Song J., Mershon J., Barrett-Connor E. 2008
Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Grady D., Ettinger B., Moscarelli E., Plouffe L., Sarkar S., Ciaccia A., Cummings S. 2004
Raloxifene reduces risk of vertebral fractures corrected in postmenopausal women regardless of prior hormone therapy. Johnell O., Cauley JA., Kulkarni PM., Wong M., Stock JL. 2004
Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Keech CA., Sashegyi A., Barrett-Connor E. 2005
Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Land SR., Wickerham DL., Costantino JP., Ritter MW., Vogel VG., Lee M., Pajon ER., Wade JL., Dakhil S., Lockhart JB., Wolmark N., Ganz PA. 2006
Safety assessment of raloxifene over eight years in a clinical trial setting. Martino S., Disch D., Dowsett SA., Keech CA., Mershon JL. 2005
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. Maunsell E., Goss PE., Chlebowski RT., Ingle JN., Alés-Martínez JE., Sarto GE., Fabian CJ., Pujol P., Ruiz A., Cooke AL., Hendrix S., Thayer DW., Rowland KM., Dubé P., Spadafora S., Pruthi S., Lickley L., Ellard SL., Cheung AM., Wactawski-Wende J., Gelmon KA., Johnston D., Hiltz A., Brundage M., Pater JL., Tu D., Richardson H. 2014
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Powles T., Eeles R., Ashley S., Easton D., Chang J., Dowsett M., Tidy A., Viggers J., Davey J. 1998
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Sestak I., Singh S., Cuzick J., Blake GM., Patel R., Gossiel F., Coleman R., Dowsett M., Forbes JF., Howell A., Eastell R. 2014
Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. Silverman SL., Delmas PD., Kulkarni PM., Stock JL., Wong M., Plouffe L. 2004
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. Siris ES., Harris ST., Eastell R., Zanchetta JR., Goemaere S., Diez-Perez A., Stock JL., Song J., Qu Y., Kulkarni PM., Siddhanti SR., Wong M., Cummings SR. 2005
Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. Spagnolo F., Sestak I., Howell A., Forbes JF., Cuzick J. 2016
Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Veronesi U., Maisonneuve P., Costa A., Sacchini V., Maltoni C., Robertson C., Rotmensz N., Boyle P. 1998
Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. Veronesi U., Maisonneuve P., Rotmensz N., Costa A., Sacchini V., Travaglini R., D'Aiuto G., Lovison F., Gucciardo G., Muraca MG., Pizzichetta MA., Conforti S., Decensi A., Robertson C., Boyle P. 2003
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Vogel VG., Costantino JP., Wickerham DL., Cronin WM., Cecchini RS., Atkins JN., Bevers TB., Fehrenbacher L., Pajon ER., Wade JL., Robidoux A., Margolese RG., James J., Runowicz CD., Ganz PA., Reis SE., McCaskill-Stevens W., Ford LG., Jordan VC., Wolmark N. 2010
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Cuzick J., Forbes J., Edwards R., Baum M., Cawthorn S., Coates A., Hamed A., Howell A., Powles T. 2002
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. Cuzick J., Forbes JF., Sestak I., Cawthorn S., Hamed H., Holli K., Howell A. 2007
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Cuzick J., Sestak I., Forbes JF., Dowsett M., Knox J., Cawthorn S., Saunders C., Roche N., Mansel RE., von Minckwitz G., Bonanni B., Palva T., Howell A. 2014
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Fisher B., Costantino JP., Wickerham DL., Cecchini RS., Cronin WM., Robidoux A., Bevers TB., Kavanah MT., Atkins JN., Margolese RG., Runowicz CD., James JM., Ford LG., Wolmark N. 2005
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Fisher B., Costantino JP., Wickerham DL., Redmond CK., Kavanah M., Cronin WM., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. 1998
Exemestane for breast-cancer prevention in postmenopausal women. Goss PE., Ingle JN., Alés-Martínez JE., Cheung AM., Chlebowski RT., Wactawski-Wende J., McTiernan A., Robbins J., Johnson KC., Martin LW., Winquist E., Sarto GE., Garber JE., Fabian CJ., Pujol P., Maunsell E., Farmer P., Gelmon KA., Tu D., Richardson H. 2011
Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Lippman ME., Cummings SR., Disch DP., Mershon JL., Dowsett SA., Cauley JA., Martino S. 2006
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. Powles TJ., Ashley S., Tidy A., Smith IE., Dowsett M. 2007
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. Veronesi U., Maisonneuve P., Rotmensz N., Bonanni B., Boyle P., Viale G., Costa A., Sacchini V., Travaglini R., D'Aiuto G., Oliviero P., Lovison F., Gucciardo G., del Turco MR., Muraca MG., Pizzichetta MA., Conforti S., Decensi A. 2007
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Vogel VG., Costantino JP., Wickerham DL., Cronin WM., Cecchini RS., Atkins JN., Bevers TB., Fehrenbacher L., Pajon ER., Wade JL., Robidoux A., Margolese RG., James J., Lippman SM., Runowicz CD., Ganz PA., Reis SE., McCaskill-Stevens W., Ford LG., Jordan VC., Wolmark N. 2006
Tamoxifen and mammographic breast densities. Brisson J., Brisson B., Coté G., Maunsell E., Bérubé S., Robert J. 2000
Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. Bruno S., Maisonneuve P., Castellana P., Rotmensz N., Rossi S., Maggioni M., Persico M., Colombo A., Monasterolo F., Casadei-Giunchi D., Desiderio F., Stroffolini T., Sacchini V., Decensi A., Veronesi U. 2005
Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Chalas E., Costantino JP., Wickerham DL., Wolmark N., Lewis GC., Bergman C., Runowicz CD. 2005
A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Christodoulakos GE., Botsis DS., Lambrinoudaki IV., Papagianni VD., Panoulis CP., Creatsa MG., Alexandrou AP., Augoulea AD., Dendrinos SG., Creatsas GC. 2006
Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Cohen FJ., Watts S., Shah A., Akers R., Plouffe L. 2000
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. Delmas PD., Bjarnason NH., Mitlak BH., Ravoux AC., Shah AS., Huster WJ., Draper M., Christiansen C. 1997
Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. Ensrud KE., Stock JL., Barrett-Connor E., Grady D., Mosca L., Khaw KT., Zhao Q., Agnusdei D., Cauley JA. 2008
Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Johnston CC., Bjarnason NH., Cohen FJ., Shah A., Lindsay R., Mitlak BH., Huster W., Draper MW., Harper KD., Heath H., Gennari C., Christiansen C., Arnaud CD., Delmas PD. -- Not Found --
Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Jolly EE., Bjarnason NH., Neven P., Plouffe L., Johnston CC., Watts SD., Arnaud CD., Mason TM., Crans G., Akers R., Draper MW. -- Not Found --
Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. Lufkin EG., Whitaker MD., Nickelsen T., Argueta R., Caplan RH., Knickerbocker RK., Riggs BL. 1998
Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. McClung MR., Siris E., Cummings S., Bolognese M., Ettinger M., Moffett A., Emkey R., Day W., Somayaji V., Lee A. -- Not Found --
Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Meunier PJ., Vignot E., Garnero P., Confavreux E., Paris E., Liu-Leage S., Sarkar S., Liu T., Wong M., Draper MW. 1999
Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Morii H., Ohashi Y., Taketani Y., Fukunaga M., Nakamura T., Itabashi A., Sarkar S., Harper K. 2003
Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Nickelsen T., Lufkin EG., Riggs BL., Cox DA., Crook TH. 1999
Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate. Palacios S., Farias ML., Luebbert H., Gomez G., Yabur JA., Quail DC., Turbi C., Kayath MJ., Almeida MJ., Mönnig E., Nickelsen T. 2004
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). Runowicz CD., Costantino JP., Wickerham DL., Cecchini RS., Cronin WM., Ford LG., Vogel VG., Wolmark N. 2011
Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. Abramson N., Costantino JP., Garber JE., Berliner N., Wickerham DL., Wolmark N. 2006

Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: